Pivotal trials and novel combinations have started, but four programmes seem to have been discontinued.
ApexOnco Front Page
Recent articles
Varseta-M efficacy wanes, but more than justifies a pivotal trial.
Precemtabart tocentecan could soon become the industry's most advanced anti-CEACAM5 ADC.
Ono's antisense therapy is to begin its first pivotal trial.
The Kandlelit-013 trial of calderasib plus Keytruda in adjuvant NSCLC will start in April.
A trial of one KRAS G12D inhibitor is halted early, while that of another sees tox troubles.
The group’s first pivotal readout, in second-line pancreatic cancer, is coming.
The Japanese group will soon start a trial of its Reblozyl rival in first-line MDS.
